Thrombin Inhibitor Peptides for Stroke Reperfusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thrombolytic therapies for ischemic stroke, such as tPA, have limitations including incomplete re-canalization and increased risk of re-occlusion and intracranial hemorrhage, highlighting the need for effective thrombin inhibitors that can improve stroke outcomes.
Innovation Solution
Development of peptides that bind to thrombin's exosite II, competitively inhibiting fibrinogen binding and preventing fibrin formation, potentially used in conjunction with tPA to enhance re-canalization and reduce bleeding risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If tPA therapy is used to promote rapid reperfusion of the ischaemic brain, then blood flow through the affected vessel is improved, but the risk of intracranial haemorrhage is increased and re-occlusion occurs
Solution Approach 1:
The patent introduces a novel thrombin inhibitor as an intermediary agent that works in conjunction with tPA. This inhibitor mediates the harmful effects of thrombin (which promotes clot formation and prevents reperfusion) without interfering with tPA's ability to dissolve existing clots. The dual mechanism allows simultaneous clot dissolution and prevention of new clot formation, resolving the contradiction between improving reperfusion and reducing hemorrhage risk
Solution Approach 2:
The thrombin inhibitor provides preliminary anti-action by preventing thrombin from converting fibrinogen to fibrin before tPA can dissolve the clot. By blocking thrombin activity in advance, the inhibitor prevents re-occlusion and reduces the risk of intracranial hemorrhage while tPA is performing its thrombolytic function, thus protecting against the harmful effects that would otherwise counteract the reperfusion benefit
2Reliability
If thrombin inhibitors are used to improve vessel re-canalisation, then clot dissolution is enhanced, but the risk of bleeding is increased
Solution Approach 1:
The patent employs parameter changes by designing a thrombin inhibitor with specific molecular characteristics (peptide structure with defined amino acid sequence) that optimize its binding affinity to thrombin while controlling its anticoagulant potency. By carefully adjusting the inhibitor's structural parameters, the patent achieves effective thrombin inhibition that improves re-canalisation while minimizing excessive anticoagulation and associated bleeding risks
3Productivity
If the dose of tPA is increased to improve thrombolytic therapy effectiveness, then clot dissolution is enhanced, but the incidence of intracranial haemorrhage increases
Solution Approach 1:
The thrombin inhibitor serves as a protective intermediary that allows higher doses of tPA to be administered safely. By blocking thrombin's pro-coagulant activity, the inhibitor counterbalances the increased hemorrhage risk associated with higher tPA doses, enabling the system to achieve better thrombolytic effectiveness without proportionally increasing intracranial hemorrhage incidence
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate potent anticoagulant activity with reduced clotting and bleeding times compared to hirudin, offering improved thrombin inhibition with potential for enhanced ischemic stroke treatment outcomes.
Implementation Method 1
the peptide competitively inhibits the binding of clot-associated fibrin, preferably fibrinogen γ′, to exosite II of thrombin
Data Source
AI summary
The treatment of stroke related diseases are described herein. In addition, fibrin clot formation and related activity is proposed for the disclosed compounds, in particular, peptides for inhibiting or modifying the cleavages of fibrinogen by thrombin. Methods for producing such compounds are also disclosed.